Evidence map›Paper›PMID 31786255›Full record

ArticleThe journal of allergy and clinical immunology. In practice2020

Global Trends in Anaphylaxis Epidemiology and Clinical Implications.

Paul J Turner, Dianne E Campbell, Megan S Motosue, Ronna L Campbell

Open access · hybridAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 5 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 5 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Predictors of Fatal Anaphylaxis: A Systematic Review.International archives of allergy and immunology · 2026
    Pooled it
  3. Pooled it
  4. Probiotics in infants for prevention of allergic disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  5. Pooled it
  6. Trial
  7. Needle-to-bone safety margin of adrenaline auto-injectors in Japanese children: Impact of injection site variation.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Anaphylaxis: Clinical Criteria, Severity, and Clinical Courses.Immunology and allergy clinics of North America · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Global Burden of Drug-Induced Anaphylaxis Associated With 33 Classes of Antibiotics (1968-2024): A Pharmacovigilance Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Paul J TurnerSection of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom; Discipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia.
Dianne E CampbellDiscipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia; Department of Allergy and Immunology, Children's Hospital at Westmead, Sydney, NSW, Australia.
Megan S MotosueDepartment of Allergy and Immunology, University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii.
Ronna L CampbellDepartment of Emergency Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minn. Electronic address: campbell.ronna@mayo.edu.
Imperial College London · GBMayo Clinic · USUniversity of Hawaiʻi at Mānoa · USUniversity of Sydney · AU

Funding

Medical Research Council MR/K010468/1
6 · The paper itself

Abstract

The true global scale of anaphylaxis remains elusive, because many episodes occur in the community without presentation to health care facilities, and most regions have not yet developed reliable systems with which to monitor severe allergic events. The most robust data sets currently available are based largely on hospital admissions, which are limited by inherent issues of misdiagnosis, misclassification, and generalizability. Despite this, there is convincing evidence of a global increase in rates of all-cause anaphylaxis, driven largely by medication- and food-related anaphylaxis. There is no evidence of parallel increases in global all-cause anaphylaxis mortality, with surprisingly similar estimates for case-fatality rates at approximately 0.5% to 1% of fatal outcomes for hospitalizations due to anaphylaxis across several regions. Studying regional patterns of anaphylaxis to certain triggers have provided valuable insights into susceptibility and sensitizing events: for example, the link between the mAb cetuximab and allergy to mammalian meat. Likewise, data from published fatality registers can identify potentially modifiable risk factors that can be used to inform clinical practice, such as prevention of delayed epinephrine administration, correct posturing during anaphylaxis, special attention to populations at risk (such as the elderly on multiple medications), and use of venom immunotherapy in individuals at risk of insect-related anaphylaxis.

Indexed as

AnaphylaxisAgedAnimalsDesensitization, ImmunologicEpinephrineHumansPopulation GroupsRisk FactorsEpinephrineAnaphylaxisBiphasicEpidemiologyFood allergyTime trends

Identifiers

PMID31786255
PMCPMC7152797
OpenAlexW2991634674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.